Navigation Links
Phase III data show investigational compound empagliflozin significantly reduced blood glucose in adults with type 2 diabetes
Date:6/22/2013

ut Diabetes
Approximately 25.8 million Americans3 and an estimated 371 million people worldwide4 have type 1 or type 2 diabetes. T2D is the most common type, accounting for an estimated 90 to 95 percent of all diabetes cases.3 Diabetes is a chronic condition that occurs when the body does not properly produce or use the hormone insulin.5 Diabetes was estimated to cost the U.S. $245 billion in 2012.6

Boehringer Ingelheim and Eli Lilly and Company
In January 2011, Boehringer Ingelheim and Eli Lilly and Company announced an alliance in the field of diabetes that centers on three compounds representing several of the largest diabetes treatment classes. This alliance leverages the companies' strengths as two of the world's leading pharmaceutical companies, combining Boehringer Ingelheim's solid track record of research-driven innovation and Lilly's innovative research, experience, and pioneering history in diabetes. By joining forces, the companies demonstrate commitment in the care of people with diabetes and stand together to focus on patient needs. Find out more about the alliance at www.boehringer-ingelheim.com or www.lilly.com.

About Boehringer Ingelheim
Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 140 affiliates and more than 46,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of hig
'/>"/>

SOURCE Eli Lilly and Company; Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Follow-up Phase II Data Analysis Adds to Body of Evidence for Investigational Novel Basal Insulin, LY2605541
2. Phase III data show significant reduction in blood glucose with investigational compound empagliflozin added to metformin or metformin plus sulfonylurea in adults with type 2 diabetes
3. Sanofi Announces Positive Phase 3 Data for Once-Daily Lixisenatide for Type 2 Diabetes
4. Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine
5. Safinamide Phase III Study Results Presented at 2013 MDS Meeting
6. Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinsons Disease
7. Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder
8. AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting
9. Updated Results of Two Phase 2 Ibrutinib Studies in Patients with Mantle Cell Lymphoma or Diffuse Large B-cell Lymphoma
10. Ibrutinib Phase 2 Data: Analyses Show Efficacy with Ibrutinib Monotherapy in Patients with Relapsed or Refractory Mantle Cell or Diffuse Large B-cell Lymphoma
11. Lilly Voluntarily Terminates Phase II Study for LY2886721, a Beta Secretase Inhibitor, Being Investigated as a Treatment for Alzheimers Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Cord Blood America, Inc. ( www.cordblood-america.com ) (OTC Bulletin Board: ... Preliminary Proxy Statement, Schedule 14A, with the U.S. Securities & ... for shareholders detailing why a "YES" vote to increase the ... As we reflect upon the 2014 fiscal year ...
(Date:1/23/2015)... , Jan. 23, 2015  CytoSorbents Corporation (NASDAQ CM: ... CytoSorb® extracorporeal cytokine adsorber to reduce deadly inflammation ... receipt of $385,642, net of transaction costs, in ... Technology Business Tax Certificate Transfer Program sponsored by ...
(Date:1/23/2015)... BIRMINGHAM, Ala. , Jan. 23, 2015 Gem ... (STS) patients have been enrolled into the Company,s Phase ... efficacy and safety of Gem,s lead compound, GPX-150 (an ... for advanced or metastatic disease. Logo - ...
Breaking Medicine Technology:Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2
... Bayer HealthCare LLC announced today that it has ... and Farnam Companies Inc. over Farnam,s advertising for its ... of the settlement, Farnam has agreed to withdraw the ... campaign included claims that Bio Spot® was "as effective ...
... CLARA, Calif., June 17, 2011 NewCardio, Inc., (OTC ... that Vincent Renz, Chief Executive Officer, is scheduled to ... Conference is on June 22 and 23, 2011, at ... 3:30 p.m. ET on Wednesday, June 22. ...
Cached Medicine Technology:Bayer Announces Farnam Companies' Agreement to Halt Disputed Bio Spot® Ads 2NewCardio to Present at Wells Fargo Securities Healthcare Conference 2NewCardio to Present at Wells Fargo Securities Healthcare Conference 3
(Date:1/22/2015)... AngelWeddingDress, the premier women’s dress supplier, has recently ... View website of AngelWeddingDress.com to find more details. ... online for a bridal party. AngelWeddingDress offers a variety ... Its maternity wedding dresses are specially designed for 2015. ...
(Date:1/22/2015)... A new white paper by The ... in the long-term care environment as well as provides ... The paper, “The Power of Person-Centeredness in Long-Term Care: ... of the patient, resident and family experience in long-term ...
(Date:1/22/2015)... Oceanside,CA (PRWEB) January 22, 2015 For over 20 ... the Oceanside and Vista area has treated just about ... other personal injury circumstances. And for those same twenty-plus years, ... victims of all those injuries with the best possible doctor. ...
(Date:1/22/2015)... NY (PRWEB) January 22, 2015 ... of Sports Medicine flagship journal Medicine & Science ... L-Citrulline before exercise may help reduce gastrointestinal (GI) ... 1 , Participants in the double-blind, placebo-controlled ...
(Date:1/22/2015)... January 22, 2015 IsoComforter, Inc. has introduced ... with patented IsoTube design to treat specific body parts and ... most progressive and easy to use patented cold therapy machine ... sports related orthopedic and muscle injuries. IsoComforter has become ...
Breaking Medicine News(10 mins):Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2
... Hanover Insurance Group, Inc. (NYSE: THG ... to the company,s board of directors at its ... principal of Taggart Associates in Cambridge, Mass., which ... work on corporate and non-profit boards.(Logo: http://www.newscom.com/cgi-bin/prnh/20051031/NEM023LOGO ...
... men discuss use of medicines such as Propecia with their ... with no signs of prostate cancer may wish to talk ... reduce their risk for the disease, new guidelines suggest. , ... Urological Association have issued new guidelines recommending that these men ...
... field needs more rigorous trials to aid doctors, , , TUESDAY, ... for cardiac care issued by the American Heart Association and ... kind of gold-standard evidence that doctors respect most, a new ... crying in the wilderness. One author of the report, published ...
... N.J., Feb. 24 Nephros, Inc. ... developing and marketing filtration products for therapeutic applications, ... is has received initial responses from the FDA,s ... devices. 510k Application for OLpur MD220 Dialyzers ...
... of Women,s Hair LossHOUSTON, Feb. 24 When you find ... keep your ponytail tight, it may be hair loss that ... in the hair care market as more and more women ... For most women, hair loss isn,t about going bald; ...
... A project to create awareness among,African American women about ... will begin in the Chicago area in March,led by ... Lawson and Dr. Eric Brown. According to the ... are 2 to 3 times more likely to get,uterine ...
Cached Medicine News:Health News:The Hanover Insurance Group Elects Harriett Tee Taggart to Board of Directors 2Health News:The Hanover Insurance Group Elects Harriett Tee Taggart to Board of Directors 3Health News:Drugs May Help Healthy Men Lower Prostate Cancer Risk 2Health News:Weak Evidence Backs Most Heart Guidelines, Report Finds 2Health News:Weak Evidence Backs Most Heart Guidelines, Report Finds 3Health News:Nephros Provides Update on 510k Applications 2Health News:Nephros Provides Update on 510k Applications 3Health News:Nephros Provides Update on 510k Applications 4Health News:Take the Ponytail Test 2Health News:Prominent Chicago Gynecologists Launch Treatment Project To Raise Awareness Among African American Women of Non-Invasive Ultrasound Uterine Fibroid Procedure 2Health News:Prominent Chicago Gynecologists Launch Treatment Project To Raise Awareness Among African American Women of Non-Invasive Ultrasound Uterine Fibroid Procedure 3
... The CKX microscopes utilize ... improved visibility and operability in ... a cost-effective inverted microscope suited ... range of fields--from tissue culture ...
The simplest, neatest, most efficient anti-theft system for frames and sunwear. Available in 3 colors Black, Matte aluminum, and Bronze. Fits with any style or color of furniture. Safe, simple, easy...
69" 5 shelves electric rotating display with gunmetal grey frame. Lead time 6-8 weeks....
1 Frame clear base post with transparent Eyevee 2.0 Clip....
Medicine Products: